Please assess the completion status of the following clinical trial:

Trial Title: A Study of Abemaciclib (LY2835219) in Combination With Fulvestrant Compared to Chemotherapy in Women With HR Positive, HER2 Negative Metastatic Breast Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Participants must be females of post-menopausal status with HR+, HER2- breast cancer that has spread to internal organs~* Participants must have had at least one endocrine therapy~* Participants must be willing to use a device to answer daily questions about how they are doing for the duration of their participation in the study~* If participant has diarrhea from a previous treatment, they should talk to their doctor to ensure they have recovered enough to participate in this study~Exclusion Criteria:~* Participants must not have breast cancer that has spread to the brain if untreated and with symptoms~* Participants must not have had any systemic treatment after their breast cancer has spread unless it is endocrine therapy~* Participants must not have certain active infections including HIV or hepatitis~* Participants must not be pregnant or breastfeeding~* Participants must not have certain types of cancers or certain previous cancer treatments~* Participants must not have certain serious medical conditions, including heart or lung disease, or have had certain types of tissue or organ transplants

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Abemaciclib + Fulvestrant (Type: EXPERIMENTAL): 150 milligram (mg) Abemaciclib given orally twice a day (BID) with 500 mg fulvestrant given by intramuscular (IM) injection on Cycle 1 Day 1 (C1D1) and Cycle 1 Day 15 (C1D15), then Day 1 of each subsequent cycle.
- Standard Chemotherapy (Type: ACTIVE_COMPARATOR): Standard chemotherapy of physician's choice (capecitabine, docetaxel, nab paclitaxel, or paclitaxel), administered according to product label.

Based on this trial design, predict the completion outcome and termination type (if applicable).